Review Article
Year: 2020 | Month: July-September | Volume: 5 | Issue: 3 | Pages: 77-82
Non-Invasive Prenatal Tests (NIPT): Review Article
Maged MN1, Mohamed MN2, Lamia H.Shehata3
1Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of OB/GYN,
2King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Surgery,
3Care National Hospital, Department of Radiology
Corresponding Author: Maged MN
ABSTRACT
No single innovation in the past has made such a fast and massive effect on clinical obstetric practice as the introduction of noninvasive pre-natal screening (NIPS) for chromosomal abnormalities using fetal cell DNA in maternal plasma. In any case, the innovation of NIPS which has likewise been called noninvasive pre-natal testing (NIPT) is quickly advancing. Most clinicians will be unable to completely comprehend this new innovation to empower great clinical practice. This review will be centered around issues that have significant clinical ramifications. NIPT/S is just a screening test and every positive case must be affirmed by intrusive demonstrative strategies. Despite the fact that NIPT/S is being extended quickly to cover different chromosomes and huge chromosomal basic variations from the norm, the location rate is still unsure, and the positive prescient worth is required to be lower. Pregnant women who are at risk of chromosomal abnormalities other than basic trisomies ought to be offered a demonstrative test rather than NIPT/S. The utilization of NIPT/S as a primary Down syndrome screening test should not replace the 11–13 weeks scan.
Keywords: Noninvasive prenatal screening, NIPS, NIPT, Cell- free DNA , Maternal plasma, Aneuploidy